169 related articles for article (PubMed ID: 30178083)
1. Measuring the bioactivity of anti-IL-6/anti-IL-6R therapeutic antibodies: presentation of a robust reporter gene assay.
Yu C; Cao J; Wang L; Yang Y; Ni Y; Wang J
Anal Bioanal Chem; 2018 Nov; 410(27):7067-7075. PubMed ID: 30178083
[TBL] [Abstract][Full Text] [Related]
2. Development of a robust reporter gene based assay for the bioactivity determination of IL-5-targeted therapeutic antibodies.
Fu Z; Yu C; Wang L; Gao K; Xu G; Wang W; Cao J; Wang J
J Pharm Biomed Anal; 2018 Jan; 148():280-287. PubMed ID: 29059618
[TBL] [Abstract][Full Text] [Related]
3. A robust reporter assay for the determination of the bioactivity of IL-4R-targeted therapeutic antibodies.
Yu X; Yu C; Wang K; Liu C; Wang L; Wang J
J Pharm Biomed Anal; 2021 May; 199():114033. PubMed ID: 33774455
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a reliable cell-based reporter gene assay for measuring bioactivities of therapeutic anti-interleukin-23 monoclonal antibodies.
Huang J; Wang L; Yu C; Fu Z; Liu C; Zhang H; Wang K; Guo X; Wang J
Int Immunopharmacol; 2020 Aug; 85():106647. PubMed ID: 32504997
[TBL] [Abstract][Full Text] [Related]
5. A reporter gene assay for measuring the bioactivity of anti-LAG-3 therapeutic antibodies.
Wang L; Yu C; Wang K; Wang J
Luminescence; 2020 Dec; 35(8):1408-1415. PubMed ID: 32598535
[TBL] [Abstract][Full Text] [Related]
6. Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodies.
Zhao X; Qian W; Hou S; Wu Y; Guo H; Xu J; Zhang D; Li J; Fu R; Xu M; Wang F
J Pharm Biomed Anal; 2024 Aug; 245():116185. PubMed ID: 38723556
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the mechanism of action of anti-human interleukin-6 and anti-human interleukin-6 receptor-neutralising monoclonal antibodies.
Kalai M; Montero-Julian FA; Brakenhoff JP; Fontaine V; De Wit L; Wollmer A; Brailly H; Content J; Grötzinger J
Eur J Biochem; 1997 Nov; 249(3):690-700. PubMed ID: 9395315
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
9. Development of a robust reporter gene assay for measuring the bioactivity of OX40-targeted therapeutic antibodies.
Li M; Wang L; Yu C; Wang J
Luminescence; 2021 Jun; 36(4):885-893. PubMed ID: 33382183
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 as a key player in systemic inflammation and joint destruction.
Fonseca JE; Santos MJ; Canhão H; Choy E
Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
13. The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Van Roy M; Ververken C; Beirnaert E; Hoefman S; Kolkman J; Vierboom M; Breedveld E; 't Hart B; Poelmans S; Bontinck L; Hemeryck A; Jacobs S; Baumeister J; Ulrichts H
Arthritis Res Ther; 2015 May; 17(1):135. PubMed ID: 25994180
[TBL] [Abstract][Full Text] [Related]
14. Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling.
Hashizume M; Mihara M
Rheumatol Int; 2009 Feb; 29(4):397-401. PubMed ID: 18802703
[TBL] [Abstract][Full Text] [Related]
15. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
Ho LJ; Luo SF; Lai JH
Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of humanized anti-interleukin-6 receptor antibody (tocilizumab) on glioma cell proliferation. Laboratory investigation.
Kudo M; Jono H; Shinriki S; Yano S; Nakamura H; Makino K; Hide T; Muta D; Ueda M; Ota K; Ando Y; Kuratsu J
J Neurosurg; 2009 Aug; 111(2):219-25. PubMed ID: 19326989
[TBL] [Abstract][Full Text] [Related]
17. A robust and stable reporter gene bioassay for anti-IgE antibodies.
Guo S; Yu C; Wang Y; Zhang F; Cao J; Zheng C; Wang L
Anal Bioanal Chem; 2020 Mar; 412(8):1901-1914. PubMed ID: 32030491
[TBL] [Abstract][Full Text] [Related]
18. Development of a robust reporter-based assay for the bioactivity determination of anti-VEGF therapeutic antibodies.
Wang L; Xu GL; Gao K; Wilkinson J; Zhang F; Yu L; Liu CY; Yu CF; Wang WB; Li M; Chen W; Fan F; Cong M; Wang JZ
J Pharm Biomed Anal; 2016 Jun; 125():212-8. PubMed ID: 27042807
[TBL] [Abstract][Full Text] [Related]
19. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
20. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
